文献速递自身免疫性与大疱性皮肤病

寻常型天疱疮一线利妥昔单抗与标准激素方案的真实费用比较:法国全国多中心试验数据

Comparison of real costs in the French healthcare system in newly diagnosed patients with pemphigus for first-line treatment with rituximab vs. standard corticosteroid regimen: data from a national multicentre trial.
PubMed 文献 · Br J Dermatol · 2020-01-15

基于Ritux3试验,比较寻常型天疱疮一线利妥昔单抗+短期泼尼松与单用泼尼松的直接费用。3年随访中,利妥昔单抗组人均总费用为€14 818,标准激素组为€13 997,利妥昔单抗组每例多€821(+6%)。利妥昔单抗初始费用较高,但被标准激素组持续疾病活动/复发及不良事件处理费用抵消。

要点

  • 利妥昔单抗一线治疗3年人均总费用较标准激素组高€821(+6%)。
  • 利妥昔单抗组不良事件处理费用(€2468)低于标准激素组(€4352)。
  • 药物年费用差异从第1年+€3597降至第3年-€1589。

核心结论

  • 寻常型天疱疮一线利妥昔单抗治疗3年人均总费用略高于标准激素方案,每例多€821(+6%)。

研究设计与样本

  • 基于Ritux3随机对照试验,比较利妥昔单抗+短期泼尼松与单用泼尼松两种方案,随访3年,估算直接费用。

主要发现

  • 3年随访人均总费用:标准激素组€13 997,利妥昔单抗组€14 818,差异€821(+6%)。
  • 药物年费用差异从第1年+€3597变为第3年-€1589。
  • 不良事件处理人均费用:标准激素组€4352,利妥昔单抗组€2468。

临床怎么用

  • 评估天疱疮一线治疗费用时,需综合考虑药物初始费用与复发及不良事件处理费用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rituximab has been demonstrated to be highly effective as a first-line treatment for moderate-to-severe pemphigus; however, its high cost can be considered a limitation of this treatment. OBJECTIVES: To compare direct costs of two regimens, rituximab + short-term prednisone vs. prednisone alone, tested in the Ritux3 trial. METHODS: Patients were randomly assigned to receive 2 g of rituximab and two 500-mg maintenance infusions at month 12 and month 18 along with low doses of prednisone for 3-6 months, or high doses of prednisone alone tapered over 12-18 months. We estimated the direct costs related to (i) protocol (treatments, consultations, hospitalizations); (ii) unfavourable disease course (relapse); and (iii) adverse events in both treatment groups during a 3-year follow-up. RESULTS: Annual individual cost discrepancies related to drugs decreased from +€3597 to -€1589 from the first to the third year, which corresponded to an initially higher cost in the rituximab group, counterbalanced during follow-up by costs related to treatment of patients with persistent disease activity/relapses in the standard corticosteroid (CS) group. Individual costs relating to treatment of adverse events were higher in the standard CS group (€4352) than in the rituximab group (€2468). Overall, mean individual total cost over the 3 years of follow-up was €13 997 in the standard CS arm vs. €14 818 in the rituximab arm, corresponding to a difference of €821 more per patient (+6%). CONCLUSIONS: First-line treatment of pemphigus with rituximab results in a slightly greater cost compared with a standard CS regimen. What's already known about this topic Rituximab is the most effective treatment for moderate-to-severe pemphigus. Rituximab cost might be considered as a limitation of this treatment. What does this study add? After 3 years of follow-up, mean individual total cost for a patient with first-line treatment with rituximab was €14 818 vs. €13 997 with standard corticosteroids (CS), resulting in a slightly higher cost of €821 (+6%). The initially greater cost of rituximab was counterbalanced by costs related to management of flares/relapses in patients treated with a standard CS regimen.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Hébert V, Vermeulin T, Tanguy L, et al. Comparison of real costs in the French healthcare system in newly diagnosed patients with pemphigus for first-line treatment with rituximab vs. standard corticosteroid regimen: data from a national multicentre trial. Br J Dermatol. 2020. PMID: 31657454. doi:10.1111/bjd.18563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。